Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication

European Journal of Gastroenterology and Hepatology

Volumn 28, Issue 6, 2016, Pages 676-683

  Tepeš, Bojan ^a   Vujasinović, Miroslav ^b   Šeruga, Maja ^c   Stefanovič, Milan ^d   Forte, Alenka ^e   Jeverica, Samo ^f  

^a AM DC Roga ka   (Slovenia)

^b General Hospital Slovenj Gradec   (Slovenia)

^c General Hospital Murska Sobota   (Slovenia)

^d DC Bled   (Slovenia)

^e MC Heliks   (Slovenia)

^f UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Antimicrobial resistance; Concomitant therapy; Eradication therapy; Helicobacter pylori infection; Randomized clinical trial; Sequential therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; ANTIINFECTIVE AGENT; PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CLEARANCE; COLIC; DIARRHEA; DRUG HYPERSENSITIVITY; EPIGASTRIC PAIN; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; MYALGIA; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SWEATING; TASTE DISORDER; TREATMENT DURATION; VERTIGO; VOMITING; ADOLESCENT; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ADMINISTRATION; DUODENAL ULCER; DYSPEPSIA; HELICOBACTER INFECTIONS; MICROBIOLOGY; MIDDLE AGED; PEPTIC ULCER; PHASE 4 CLINICAL TRIAL; STOMACH ULCER; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DYSPEPSIA; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PEPTIC ULCER; PROTON PUMP INHIBITORS; STOMACH ULCER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84957824910     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000590     Document Type: Article

References (29)

1. Hunt RH, Xiao SD, Megraud F, Leon-Barua R, Bazzoli F, van der Merwe S, et al. World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis 2011; 20:299-304.
2. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon ATR, Bazzoli F, et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012; 61:646-664.
3. International Agency for Research on Cancer. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61:177-240.
4. de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-615.
5. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al. Japanese Society for Helicobacter Research. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010; 15:1-20.
6. Tepeš B, Štabuc B. Slovenian Society for Gastroenterology and Hepatology Guidelines on the management of Helicobacter pylori infection. Zdrav Vestn 2011; 80:647-656.
7. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62:34-42.
8. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808-1825.
9. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24:1587-1600.
10. Hu FL, Hu PJ, Liu WZ, De Wang J, Lv NH, Xiao SD, et al. Third Chinese National Consensus Report on the management of Helicobacter pylori infection. J Dig Dis 2008; 9:178-184.
11. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59:1143-1153.
12. Vujasinović M, Jeverica S, Robač N, Dolinar U, Tepeš B. Outcome of treatment for Helicobacter pylori infection in the Carinthian region. Zdrav Vestn 2014; 83:36-44.
13. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C, et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17:719-726.
14. Katelaris PH, Forbes GM, Talley NJ, Crotty B. A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: the QUADRATE Study. Gastroenterology 2002; 123: 1763-1769.
15. Hsu PI, Wu DC, Wu JY, Graham DY. Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. Helicobacter 2011; 16:139-145.
16. Tepeš B, Vujasinović M, Šeruga M, Stefanovič M, Jeverica S. Sequential and quadruple therapies for Helicobacter pylori eradication compared with triple therapy in Slovenia: a multicenter, prospective, randomized, controlled trial. Helicobacter 2012; 17:73.
17. European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter pylori Study Group. Gut 1997; 41:8-13.
18. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5:321-331.
19. McNicholl AG, Marin AC, Molina-Infante J, Castro M, Barrio J, Ducons J, et al. Participant Centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63:244-249.
20. Gisbert JP, Nyssen OP, McNicholl AG, Megraud F, Savarino V, Oderda G, et al. Meta-analysis of sequential versus standard triple therapy for Helicobacter pylori eradication. Helicobacter 2011; 16:131.
21. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, et al. Taiwan Helicobacter Consortium. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381:205-213.
22. Tepeš B, Zvezdana O. Cumulative Helicobacter pylori eradication rates in Slovenia in the year 2008. Zdrav Vestn 2010; 79:19-24.
23. Al-Eidan FA, McElnay JC, Scott MG, McConnell JB. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br J Clin Pharmacol 2002; 53:163-171.
24. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5:23-34.
25. Kongchayanun C, Vilaichone RK, Pornthisarn B, Amornsawadwattana S, Mahachai V. Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand. Helicobacter 2012; 17:282-285.
26. Greenberg ER, Anderson GL, Morgan DR, Torres J, Chey WD, Bravo LE, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet 2011; 378:507-514.
27. Essa AS, Kramer JR, Graham DY, Treiber G. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing 'concomitant therapy' versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14:109-118.
28. Huang YK, Wu MC, Wang SS, Kuo CH, Lee YC, Chang LL, et al. Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication. J Dig Dis 2012; 13: 232-238.
29. Wu DC, Hsu PI, Wu JY, Opekun AR, Kuo CH, Wu IC, et al. Sequential and concomitant therapy with four drugs is equally effective for eradication of Helicobacter pylori infection. Clin Gastroenterol Hepatol 2010; 8:36-41.